Habil Khorakiwala says: “We have earlier signed an agreement on a profit-sharing basis for contract manufacturing with Serum Institute to make vaccines in our UK facility. This is a long 15-year agreement and we have earmarked capacity for 150 million doses for them. We are also in discussion with a global vaccine company for contract manufacturing opportunities.”